Velaglucerase alfa is an intravenous enzyme replacement therapy for Gaucher disease.1 The mechanism of action of velaglucerase alfa is presented in Figure 1. For further information on velaglucerase alfa, please consult your local prescribing information.
Mechanism of action of velaglucerase alfa1,3
C-ANPROM/INT//7568; Date of preparation: September 2020
- Shire Pharmaceuticals Ltd. VPRIV® EU Summary of Product Characteristics. Last updated August 2020.
- Stirnemann J, Belmatoug N, Camou F, et al. A review of Gaucher disease pathophysiology, clinical presentation and treatments. Int J Mol Sci 2017; 18: 441.